• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卡维地洛,一种新型抗高血压药物,可预防脂质过氧化和内皮细胞的氧化损伤。

Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells.

作者信息

Yue T L, Mckenna P J, Gu J L, Cheng H Y, Ruffolo R R, Feuerstein G Z

机构信息

Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406-0939.

出版信息

Hypertension. 1993 Dec;22(6):922-8. doi: 10.1161/01.hyp.22.6.922.

DOI:10.1161/01.hyp.22.6.922
PMID:7902335
Abstract

The protective effects of carvedilol, a new beta-adrenergic receptor blocker and vasodilating antihypertensive agent, against oxygen free radical-mediated injury were studied in cultured bovine endothelial cells and compared with five other beta-blockers. Carvedilol dose-dependently inhibited oxygen radical-induced lipid peroxidation (50% inhibition at 2.6 mumol/L) and glutathione depletion (50% inhibition at 1.8 mumol/L) in the cells. Under the same conditions, other beta-blockers--propranolol, labetalol, pindolol, atenolol, and celiprolol--had only mild or no effect. Moreover, carvedilol protected against oxygen radical--mediated cell damage, as assessed by cellular lactate dehydrogenase release, with a 50% inhibition at 4.1 mumol/L and increased the cell survival in a dose-dependent manner, whereas other beta-blockers had mild or no effects. Pretreatment of the cells with carvedilol for 7 days significantly enhanced the protective effects of carvedilol. Using 2-methyl-2-nitrosopropane as a trapping agent, the spin adduct in cell lipids was monitored by electron paramagnetic resonance. Carvedilol dose-dependently decreased the intensity of the free radical signals, indicating its free radical-scavenging ability. The prevention of oxidative injury to endothelial cells might potentially contribute to the clinical beneficial effects of carvedilol as an antihypertensive agent.

摘要

研究了新型β-肾上腺素能受体阻滞剂兼血管舒张性抗高血压药卡维地洛对培养的牛内皮细胞氧自由基介导损伤的保护作用,并与其他五种β-阻滞剂进行了比较。卡维地洛在细胞中剂量依赖性地抑制氧自由基诱导的脂质过氧化(2.6 μmol/L时抑制50%)和谷胱甘肽耗竭(1.8 μmol/L时抑制50%)。在相同条件下,其他β-阻滞剂——普萘洛尔、拉贝洛尔、吲哚洛尔、阿替洛尔和塞利洛尔——只有轻微作用或无作用。此外,通过细胞乳酸脱氢酶释放评估,卡维地洛可保护细胞免受氧自由基介导的损伤,4.1 μmol/L时抑制50%,并以剂量依赖性方式提高细胞存活率,而其他β-阻滞剂作用轻微或无作用。用卡维地洛预处理细胞7天可显著增强其保护作用。以2-甲基-2-亚硝基丙烷作为捕获剂,通过电子顺磁共振监测细胞脂质中的自旋加合物。卡维地洛剂量依赖性地降低自由基信号强度,表明其具有清除自由基的能力。预防内皮细胞氧化损伤可能有助于卡维地洛作为抗高血压药的临床有益效果。

相似文献

1
Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells.卡维地洛,一种新型抗高血压药物,可预防脂质过氧化和内皮细胞的氧化损伤。
Hypertension. 1993 Dec;22(6):922-8. doi: 10.1161/01.hyp.22.6.922.
2
Carvedilol, a new vasodilating beta adrenoceptor blocker antihypertensive drug, protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils.卡维地洛是一种新型的血管舒张性β肾上腺素能受体阻滞剂抗高血压药物,可保护内皮细胞免受由黄嘌呤 - 黄嘌呤氧化酶和中性粒细胞引发的损伤。
Cardiovasc Res. 1994 Mar;28(3):400-6. doi: 10.1093/cvr/28.3.400.
3
Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger.卡维地洛是一种新型血管扩张剂和β肾上腺素能受体拮抗剂,它也是一种抗氧化剂和自由基清除剂。
J Pharmacol Exp Ther. 1992 Oct;263(1):92-8.
4
SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant.新型抗高血压药物卡维地洛的代谢产物SB 211475是一种有效的抗氧化剂。
Eur J Pharmacol. 1994 Jan 14;251(2-3):237-43. doi: 10.1016/0014-2999(94)90405-7.
5
Carvedilol, a new beta-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils.卡维地洛是一种新型β-肾上腺素能受体拮抗剂和血管舒张性抗高血压药物,可抑制人中性粒细胞释放超氧化物。
Eur J Pharmacol. 1992 Apr 22;214(2-3):277-80. doi: 10.1016/0014-2999(92)90130-v.
6
Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection.卡维地洛,一种新型血管舒张性β受体阻滞剂,具有心血管器官保护潜力。
Eur Heart J. 1996 Apr;17 Suppl B:24-9. doi: 10.1093/eurheartj/17.suppl_b.24.
7
Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity.新型血管舒张性β受体阻滞剂卡维地洛对心肌的保护作用:抗氧化活性的潜在相关性
J Hypertens Suppl. 1993 Jun;11(4):S41-8.
8
Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper.卡维地洛,一种新型抗高血压药物,可防止巨噬细胞和铜对人低密度脂蛋白的氧化。
Atherosclerosis. 1992 Dec;97(2-3):209-16. doi: 10.1016/0021-9150(92)90133-2.
9
Carvedilol and its metabolites suppress endothelin-1 production in human endothelial cell culture.
Blood Press. 1997 Jan;6(1):24-8. doi: 10.3109/08037059709086442.
10
A potent antioxidant, SB209995, inhibits oxygen-radical-mediated lipid peroxidation and cytotoxicity.
Pharmacology. 1994 Jun;48(6):385-91. doi: 10.1159/000139205.

引用本文的文献

1
Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions-A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology.衰竭心肌细胞氧化还原生物学与病理生理学的新视角:调节心肌内氧化还原环境以进行治疗干预——意大利心脏病学会心脏细胞生物学工作组的综述文章
Oxid Med Cell Longev. 2016;2016:6353469. doi: 10.1155/2016/6353469. Epub 2016 Jan 5.
2
The inhibition in tumor necrosis factor-alpha-induced attenuation in endothelial thrombomodulin expression by carvedilol is mediated by nuclear factor-kappaB and reactive oxygen species.卡维地洛通过核因子-κB 和活性氧抑制肿瘤坏死因子-α诱导的内皮血栓调节蛋白表达减弱。
J Thromb Thrombolysis. 2010 Jan;29(1):52-9. doi: 10.1007/s11239-009-0318-2. Epub 2009 Mar 31.
3
Metabolic properties of vasodilating beta blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome.血管舒张性β受体阻滞剂的代谢特性:高血压糖尿病患者及代谢综合征患者的管理考量
J Clin Hypertens (Greenwich). 2004 Dec;6(12):690-6; quiz 697. doi: 10.1111/j.1524-6175.2004.03704.x.
4
Carvedilol: a review of its use in chronic heart failure.卡维地洛:其在慢性心力衰竭中应用的综述
Drugs. 2003;63(16):1697-741. doi: 10.2165/00003495-200363160-00006.
5
Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil.卡维地洛对多药耐药基因1(MDR1)介导的多药耐药的影响:与维拉帕米的比较。
Cancer Sci. 2003 Jan;94(1):81-6. doi: 10.1111/j.1349-7006.2003.tb01356.x.
6
PF9404C, a new slow NO donor with beta receptor blocking properties.PF9404C,一种具有β受体阻断特性的新型缓慢一氧化氮供体。
Br J Pharmacol. 1999 Dec;128(8):1713-22. doi: 10.1038/sj.bjp.0702992.
7
Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.卡维地洛。对其药理特性及在心血管疾病治疗中的应用的重新评估。
Drugs. 1997 Jul;54(1):161-85. doi: 10.2165/00003495-199754010-00015.
8
Role of the Maillard reaction in diabetes mellitus and diseases of aging.美拉德反应在糖尿病和衰老相关疾病中的作用。
Drugs Aging. 1996 Aug;9(2):69-77. doi: 10.2165/00002512-199609020-00001.